Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II caspofungin secondary prophylaxis in high-risk hematologic malignancies
2005-005210-20Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Feb 2006
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in invasive mycoses and Acute Leukaemia, sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoint: Incidence of invasive fungal infection requiring additional antifungal therapy. Started Feb 2006; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive mycosesAcute Leukaemia
Beyond the preview
Go deeper on 2005-005210-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005210-20.